Table 5.
Treatment efficacy of tenofovir in chronic hepatitis B
| Ref. | No. of patients | HBeAg | Therapy regimen | HBeAg loss (%)/seroconversion from HBeAg to anti-HBe (%) | Undetectable of HBV DNA (%) | Normalization of ALT (%) | HBsAg loss (n) |
| 1Marcellin et al[83] | 176 NUCs - treatment-naive | Positive | TDF 300 mg daily (> 48 wk) | NA/21 | 76 | 68 | 5 |
| 90 | Positive | ADF 10 mg daily (> 48 wk) | NA/18 | 13 | 54 | 0 | |
| 90 | Positive | ADF (48 wk) | NA/18 | 13 | 54 | 0 | |
| 125 | Negative | ADF (48 wk) | NA/NA | 63 | 77 | 0 | |
| 2Heathcote et al[88] | 266 | Positive | TDF (> 144 wk) | 34/26 | 71 | 74 | 20 |
| 365 | Negative | TDF (> 144 wk) | NA/NA | 87 | 81 | 0 | |
| 2Marcellin et al[91] | 266 | Positive | TDF (> 240 wk) | 49/40 | 65 | 73 | 10 |
| 375 | Negative | TDF (> 240 wk) | NA/NA | 83 | 85 | 1 |
The treatment efficacies were assessed at 48 wk1, or 144 wk2. TDF: Tenofovir; ADF: Adefovir; NA: Not available; HBeAg: Hepatitis B e antigen; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B s antigen; Anti-HBe: Antibody to HBe antigen.